Journal of Radiation and Cancer Research

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 11  |  Issue : 3  |  Page : 105--114

Radioimmunotherapy of B-cell lymphoma: In vitro investigations of 177Lu-rituximab on raji cells


Aanchal Udaynath Pareri, Darshan Babu Kambli, Jeyachitra Amirdhanayagam, Mohini Guleria, Tapas Das, Chandan Kumar, Ashutosh Dash 
 Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Chandan Kumar
Radiopharmaceuticals Division, Bhabha Atomic Research Centre, Mumbai, Maharashtra
India

Background: Rituximab is a chimeric monoclonal antibody, approved by the US Food and Drug Administration for the immunotherapy of non-Hodgkin's lymphoma (NHL).177Lu-labeled rituximab has been identified as a potential agent for the radioimmunotherapy of NHL and is presently under clinical investigations. The objective of the present study is to estimate the magnitude of apoptotic cell death and cell-cycle phase arrest. Materials and Methods: Characterization of177Lu-rituximab was performed by using instant thin-layer chromatography as well as by high-performance liquid chromatography. About 37 MBq (1 mCi) of177Lu-rituximab was incubated with Raji cells up to 48 h at 37°C in a humidified atmosphere of 5% CO2. Simultaneously, an equivalent amount of rituximab present in 37 MBq (1 mCi) of177Lu-rituximab complex was used as a vehicle control. All cell samples (treated, vehicle control, and control cells) were harvested post 24 and 48 h of incubation to perform different assays such as lactate dehydrogenase, XTT, cell viability by flowcytometer, apoptosis, and cell cycle analysis. Results: The studies revealed that177Lu-rituximab induced higher cell death and apoptosis compared to unlabeled rituximab. Similarly, an increase in cell population in G1-phase of cell cycle was observed, upon treatment of Raji cells with177Lu-rituximab complex for 24 h, while an increase in G2/M phase population was observed at 48 h of incubation. Conclusions: The present studies demonstrate that177Lu-rituximab is more effective in inducing apoptotic cell death and cell cycle-phase arrest compared to its unlabeled counterpart, indicating177Lu-rituximab may have better potential in the therapy of B-cell lymphoma.


How to cite this article:
Pareri AU, Kambli DB, Amirdhanayagam J, Guleria M, Das T, Kumar C, Dash A. Radioimmunotherapy of B-cell lymphoma: In vitro investigations of 177Lu-rituximab on raji cells.J Radiat Cancer Res 2020;11:105-114


How to cite this URL:
Pareri AU, Kambli DB, Amirdhanayagam J, Guleria M, Das T, Kumar C, Dash A. Radioimmunotherapy of B-cell lymphoma: In vitro investigations of 177Lu-rituximab on raji cells. J Radiat Cancer Res [serial online] 2020 [cited 2021 Jan 25 ];11:105-114
Available from: https://www.journalrcr.org/article.asp?issn=2588-9273;year=2020;volume=11;issue=3;spage=105;epage=114;aulast=Pareri;type=0